Form 4: Cabaletta Bio Director Shawn Tomasello Reports Stock Option Grant

Director Shawn Tomasello reports the acquisition of stock options in Cabaletta Bio, Inc.

Summary

• Shawn Tomasello, a director of Cabaletta Bio, Inc. (CABA), reported a transaction involving derivative securities.
• On June 3, 2024, Tomasello acquired 22,000 stock options with an exercise price of $10.01.
• These options vest fully on the earlier of June 3, 2025, or the date of the next annual meeting of the Corporation's stockholders.
• The options expire on June 2, 2034.
• Following the reported transaction, Tomasello directly owns 22,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding stock option grants, which is neither particularly positive nor negative. It's a routine part of corporate governance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. This filing is a routine disclosure required by the SEC for insider transactions.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Cabaletta Bio.
• The size and vesting schedule of the grant are generally aligned with industry norms for companies of similar size and stage of development.
• Comparing the exercise price and vesting terms to those of similar grants at companies like CRISPR Therapeutics or Beam Therapeutics could provide further context.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant relative to the company's outstanding shares.

Key Dates